SCHEMBL23258951

SCHEMBL23258951

Cc1cc(NCCOCCO)nc(NC(=O)Nc2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
DOT1L Q8TEK3 1/20 0.41
MAPK14 Q16539 4/20 0.41
BRAF P15056 3/20 0.41
KDR P35968 2/20 0.41
TNNI3K Q59H18 2/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
MTOR P42345 2/20 0.38
BAZ1A Q9NRL2 1/20 0.38
KCNH3 Q9ULD8 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258237 0.90 EPHX2 (0.49) EPHX2MEN1KMT2ADOT1LMAPK14
SCHEMBL23258983 0.90 BRAF (0.49) MEN1KMT2AMAPK14BRAFKDR
SCHEMBL23259006 0.89 SMN1; SMN2 (0.44) KMT2AMAPK14MAPTALDH1A1HTT
SCHEMBL23258996 0.87 DOT1L (0.48) EPHX2MEN1KMT2ADOT1LMAPK14
SCHEMBL23258226 0.87 ALDH1A1 (0.42) BRAFKDRALDH1A1TSHR
SCHEMBL23258939 0.86 KDR (0.50) BRAFKDR
SCHEMBL23258969 0.86 SLC2A1 (0.51) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL23258982 0.86 MEN1 (0.55) EPHX2MEN1KMT2ADOT1LMAPK14
SCHEMBL23259120 0.85 RAB9A (0.46) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL23258997 0.85 SMN1; SMN2 (0.49) EPHX2MEN1KMT2ADOT1LMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-11-11 US disclosed
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210114991-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MEN1 2974/4885KMT2A 501/4885
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG EPHX2 294/4885MEN1 2974/4885KMT2A 501/4885
US-20210347739-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MEN1 2974/4885KMT2A 501/4885
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG EPHX2 294/4885MEN1 2974/4885KMT2A 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.